SUPN Supernus Pharmaceuticals Inc.

36.07
+1.01  (+3%)
Previous Close 35.06
Open 35.02
Price To Book 4.17
Market Cap 1887199461
Shares 52,320,473
Volume 960,596
Short Ratio
Av. Daily Volume 583,895

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 22, 2017.
Oxtellar
Epilepsy
Phase 3 data from two of its trials released December 6, 2018 met primary endpoints. Data from final trial due March 28, 2019 noted 400mg dose met primary, but 600mg did not meet primary endpoint.
SPN-812
ADHD
Phase 3 data due 2H 2019
SPN-810
Impulsive Aggression in ADHD
Approved Aug 19, 2013.
Trokendi
Epilepsy
Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.
Trokendi
Migraine
FDA approval announced December 14, 2018 to expand label to include monotherapy treatment.
Oxtellar XR
Epilepsy
Phase 3 trial to be initiated 2H 2019.
SPN-604
Bipolar depression

Latest News

  1. A Note On Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) ROE and Debt To Equity
  2. See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
  3. Supernus' ADHD Candidate Positive in 4th Phase III Study
  4. Supernus Announces Webcast of Investor Day on April 16, 2019
  5. Shareholders Are Thrilled That The Supernus Pharmaceuticals (NASDAQ:SUPN) Share Price Increased 296%
  6. Edited Transcript of SUPN earnings conference call or presentation 8-Aug-18 1:00pm GMT
  7. Edited Transcript of SUPN earnings conference call or presentation 27-Feb-19 2:00pm GMT
  8. Supernus reports mixed ADHD drug trial results. So why isn't it worried?
  9. Supernus Announces P304 Phase III Data Confirming Positive Results from Previous Three Phase III Studies on SPN-812 in ADHD
  10. Supernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with ADHD
  11. What Investors Should Know About Supernus Pharmaceuticals, Inc.’s (NASDAQ:SUPN) Financial Strength
  12. Recent Analysis Shows Golar LNG, AG Mortgage Investment Trust, AmerisourceBergen, Caesarstone, Dycom Industries, and Supernus Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
  13. Supernus to Present at the 2019 Cowen Health Care Conference
  14. Supernus Pharmaceuticals Inc (SUPN) Files 10-K for the Fiscal Year Ended on December 31, 2018
  15. New Enterprise Associates is raising its biggest fund yet. Here's how much it's going for.
  16. Supernus Pharmaceuticals- Migraines, Epilepsy and ADHD
  17. Supernus Pharmaceuticals Inc (SUPN) Q4 2018 Earnings Conference Call Transcript
  18. Supernus Pharmaceuticals, Inc. to Host Earnings Call
  19. Supernus Announces Record Full Year 2018 Financial Results